UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Connect with industry professionals using effective methods. Discover ways to enhance your network and open new opportunities.
16,053 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Investing in AI memory and storage chips may beat chasing hype. Learn how to spot the driver, assess risk, and start ...
Ripple's XRP is the sole crypto on CNBC's 2026 Disruptor 50 list, ranked 16th and labeled 'new money.' The milestone ...
Mortgage applications fall 2.3% last week as borrowing costs move higher, signaling a cooling in home-purchase activi...
GM is rebooting its U.S. investment strategy with tighter budgets and sharper priorities. This move aims to boost nea...
Pay transparency is surfacing a bigger problem: firms publish pay ranges but struggle to explain how they set actual ...
Ripple lands on CNBC's disruptor list and announces a major prime brokerage partnership as XRP trends lower for the w...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
World Liberty Financial’s WLFI rebound opens an exit window for dormant holders, even as AI Financial cautions that t...
Bitcoin and Ethereum diverge in 2026 as institutions lean into regulated markets while Ethereum accelerates its settl...
Whale buyers snapped up hundreds of millions of DOGE as SpaceX filed for a Nasdaq debut. The surge boosts bets that d...
Quantum stocks are notoriously volatile. This guide explains why d-wave quantum stock keeps rising, what it means for...